All News

    FDA Approves Inluriyo for ER+, HER2– Metastatic Breast Cancer

    September 25th 2025, 6:38pm

    Article

    Inluriyo, an oral therapy for ER+, HER2– metastatic breast cancer with ESR1 mutations, offers a new treatment option after prior endocrine therapy.

    A Day in the Life: Growing Where I’m Planted

    September 25th 2025, 5:00pm

    Article

    Tending my garden and observing nature teaches me resilience, presence, and growth, helping me carry joy and sorrow while living with Lynch syndrome.

    Women Face Increased Anal Cancer Risk After Cervical Cancer

    September 25th 2025, 4:00pm

    Article

    Women with a history of cervical cancer are nearly twice as likely to develop anal cancer as members of the general population, according to researchers.

    New Drug Combo Shows Deeper Responses in Multiple Myeloma

    September 25th 2025, 3:00pm

    Article

    A study found that iberdomide with Darzalex and dexamethasone helped more patients with multiple myeloma reach no signs of cancer after treatment.

    Understanding Early Warning Signs of Prostate Cancer

    September 25th 2025, 1:00pm

    Video

    Dr. David A. Taub sat down with CURE for an interview in honor of Prostate Cancer Awareness Month, observed annually each September.

    Emphasizing the Importance of Food Safety During Cancer Care

    September 24th 2025, 7:00pm

    Video

    Heather Ann Yonker, emphasizes the importance of food safety practices for patients with cancer, particularly those with weakened immune systems.

    We Faced it All and We Stood Tall as Patients With Cancer

    September 24th 2025, 5:00pm

    Article

    As a 12-year survivor of myelodysplastic syndrome, I’ve learned that each of us faces cancer our own way, and in the end, we can say we lived life our way.

    First-Line Enhertu Combo Gets Priority Review in HER2+ Metastatic Breast Cancer

    September 24th 2025, 4:00pm

    Article

    The FDA granted priority review to an sBLA for first-line treatment with Enhertu plus Perjeta in unresectable or metastatic HER2-positive breast cancer.

    Research Spotlight by Dr. Anna Berkenblit: Q&A with Lynn Matrisian, PhD, MBA, Chief Science Advisor at PanCAN

    September 24th 2025, 3:44pm

    Article

    Pancreatic cancer remains one of the deadliest cancers because it is often detected at an advanced stage when treatment options are limited.

    Alnodesertib Wins FDA Fast Track Status in ATM-Negative Colorectal Cancer

    September 24th 2025, 3:01pm

    Article

    The FDA grants fast track status to alnodesertib plus low-dose irinotecan for third-line metastatic colorectal cancer with ATM deficiency.